Prothena Corporation plc has released a presentation detailing its ongoing efforts in developing life-saving therapies targeting diseases of protein dysregulation such as Alzheimer's disease, Parkinson's disease, and Transthyretin amyloidosis. The presentation highlights the significant global impact of these conditions, with over 80 million people worldwide living with early symptomatic Alzheimer's and more than 10 million affected by Parkinson's disease. Prothena's strategic collaborations with companies like Bristol Myers Squibb, Novo Nordisk, and Roche are underscored, as well as its various clinical programs, including one partnered Phase 3 program and multiple Phase 1 and 2 programs. The company emphasizes its expert epitope mapping and disease-driven antibody engineering to target proteins with the greatest effect on disease. You can access the full presentation through the link below.